Utilization of TandemHeart in Cardiogenic Shock: Insights from the THEME Registry
Presenter
Chaun M Gandolfo, DO, Henry Ford Health System, Detroit, MI
Chaun M Gandolfo, DO1, Khaldoon Alaswad, M.D., FSCAI2, Brian O'Neill, MD1, Stanley J. Chetcuti, M.D., FSCAI3, Michael Ragosta III, M.D.4, Eric B Adler, M.D.5, Andrew Thomas Coletti, M.D.6 and Babar B Basir, DO, FSCAI1, (1)Henry Ford Health System, Detroit, MI, (2)Henry Ford Hospital, Detroit, MI, (3)The University of Michigan, Ann Arbor, MI, (4)The University of Virginia School of Medicine, Charlottesville, VA, (5)UC San Diego Health, La Jolla, CA, (6)PeaceHealth St. Joseph Medical Center, bellingham, WA
Keywords: Cardiogenic shock and Hemodynamic support
Background:
TandemHeart has been shown to improve hemodynamic and metabolic complications of cardiogenic shock. Contemporary outcomes have not been reported.
Methods:
We evaluated all patients enrolled into the THEME registry from May 2015 to June 2019 who had a left sided TandemHeart device for cardiogenic shock. The THEME registry is a multi-center, prospective, observational registry.
Results:
50 patients received a TandemHeart. The average age was 55.1±13.7 years and 34% were female. 60% of patients had known CHF, 46% CAD and 26% DM. 40% presented with AKI and 24% with hepatic dysfunction. 16% of shock was secondary to an AMI and 12% secondary to acute mitral regurgitation. The average duration of support was 5.7±3.3 days. Device related complications were low. 82% of patients were alive at time of explant, 42% were transitioned to another form of MCS, 66% were alive at hospital discharge and at 180-days (Table, Figure).
Conclusions:
Contemporary use of TandemHeart in patients with cardiogenic shock is associated with favorable outcomes. 
